Copyright Reports & Markets. All rights reserved.

Global Next Generation Cancer Diagnostics Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Next Generation Cancer Diagnostics Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Next Generation Sequencing
    • 1.4.3 qPCR & Multiplexing
    • 1.4.4 DNA Microarrays
    • 1.4.5 Other
  • 1.5 Market by Application
    • 1.5.1 Global Next Generation Cancer Diagnostics Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Other
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Next Generation Cancer Diagnostics Market Perspective (2015-2026)
  • 2.2 Global Next Generation Cancer Diagnostics Growth Trends by Regions
    • 2.2.1 Next Generation Cancer Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Next Generation Cancer Diagnostics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Next Generation Cancer Diagnostics Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Next Generation Cancer Diagnostics Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Next Generation Cancer Diagnostics Players by Market Size
    • 3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2015-2020)
    • 3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Next Generation Cancer Diagnostics Market Concentration Ratio
    • 3.2.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2019
  • 3.3 Next Generation Cancer Diagnostics Key Players Head office and Area Served
  • 3.4 Key Players Next Generation Cancer Diagnostics Product Solution and Service
  • 3.5 Date of Enter into Next Generation Cancer Diagnostics Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2015-2020)
  • 4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Next Generation Cancer Diagnostics Market Size by Application (2015-2020)
  • 5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Next Generation Cancer Diagnostics Market Size (2015-2020)
  • 6.2 Next Generation Cancer Diagnostics Key Players in North America (2019-2020)
  • 6.3 North America Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
  • 6.4 North America Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Next Generation Cancer Diagnostics Market Size (2015-2020)
  • 7.2 Next Generation Cancer Diagnostics Key Players in Europe (2019-2020)
  • 7.3 Europe Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
  • 7.4 Europe Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

8 China

  • 8.1 China Next Generation Cancer Diagnostics Market Size (2015-2020)
  • 8.2 Next Generation Cancer Diagnostics Key Players in China (2019-2020)
  • 8.3 China Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
  • 8.4 China Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Next Generation Cancer Diagnostics Market Size (2015-2020)
  • 9.2 Next Generation Cancer Diagnostics Key Players in Japan (2019-2020)
  • 9.3 Japan Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
  • 9.4 Japan Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Next Generation Cancer Diagnostics Market Size (2015-2020)
  • 10.2 Next Generation Cancer Diagnostics Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

11 India

  • 11.1 India Next Generation Cancer Diagnostics Market Size (2015-2020)
  • 11.2 Next Generation Cancer Diagnostics Key Players in India (2019-2020)
  • 11.3 India Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
  • 11.4 India Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Next Generation Cancer Diagnostics Market Size (2015-2020)
  • 12.2 Next Generation Cancer Diagnostics Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
  • 12.4 Central & South America Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Cepheid
    • 13.1.1 Cepheid Company Details
    • 13.1.2 Cepheid Business Overview
    • 13.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
    • 13.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2015-2020))
    • 13.1.5 Cepheid Recent Development
  • 13.2 Koninklijke Philips N.V
    • 13.2.1 Koninklijke Philips N.V Company Details
    • 13.2.2 Koninklijke Philips N.V Business Overview
    • 13.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
    • 13.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.2.5 Koninklijke Philips N.V Recent Development
  • 13.3 F. Hoffmann-La Roche Ltd
    • 13.3.1 F. Hoffmann-La Roche Ltd Company Details
    • 13.3.2 F. Hoffmann-La Roche Ltd Business Overview
    • 13.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
    • 13.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.3.5 F. Hoffmann-La Roche Ltd Recent Development
  • 13.4 Qiagen
    • 13.4.1 Qiagen Company Details
    • 13.4.2 Qiagen Business Overview
    • 13.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
    • 13.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.4.5 Qiagen Recent Development
  • 13.5 Novartis AG
    • 13.5.1 Novartis AG Company Details
    • 13.5.2 Novartis AG Business Overview
    • 13.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
    • 13.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.5.5 Novartis AG Recent Development
  • 13.6 Abbott
    • 13.6.1 Abbott Company Details
    • 13.6.2 Abbott Business Overview
    • 13.6.3 Abbott Next Generation Cancer Diagnostics Introduction
    • 13.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.6.5 Abbott Recent Development
  • 13.7 Thermo Fisher Scientific
    • 13.7.1 Thermo Fisher Scientific Company Details
    • 13.7.2 Thermo Fisher Scientific Business Overview
    • 13.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
    • 13.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.7.5 Thermo Fisher Scientific Recent Development
  • 13.8 Opko Health
    • 13.8.1 Opko Health Company Details
    • 13.8.2 Opko Health Business Overview
    • 13.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
    • 13.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.8.5 Opko Health Recent Development
  • 13.9 Myriad Genetics
    • 13.9.1 Myriad Genetics Company Details
    • 13.9.2 Myriad Genetics Business Overview
    • 13.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
    • 13.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.9.5 Myriad Genetics Recent Development
  • 13.10 Agilent Technologies
    • 13.10.1 Agilent Technologies Company Details
    • 13.10.2 Agilent Technologies Business Overview
    • 13.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
    • 13.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 13.10.5 Agilent Technologies Recent Development
  • 13.11 GE Healthcare
    • 10.11.1 GE Healthcare Company Details
    • 10.11.2 GE Healthcare Business Overview
    • 10.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
    • 10.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 10.11.5 GE Healthcare Recent Development
  • 13.12 PerkinElmer
    • 10.12.1 PerkinElmer Company Details
    • 10.12.2 PerkinElmer Business Overview
    • 10.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
    • 10.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 10.12.5 PerkinElmer Recent Development
  • 13.13 Genomic Health
    • 10.13.1 Genomic Health Company Details
    • 10.13.2 Genomic Health Business Overview
    • 10.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
    • 10.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 10.13.5 Genomic Health Recent Development
  • 13.14 Illumina
    • 10.14.1 Illumina Company Details
    • 10.14.2 Illumina Business Overview
    • 10.14.3 Illumina Next Generation Cancer Diagnostics Introduction
    • 10.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 10.14.5 Illumina Recent Development
  • 13.15 Hologic
    • 10.15.1 Hologic Company Details
    • 10.15.2 Hologic Business Overview
    • 10.15.3 Hologic Next Generation Cancer Diagnostics Introduction
    • 10.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 10.15.5 Hologic Recent Development
  • 13.16 Almac Group
    • 10.16.1 Almac Group Company Details
    • 10.16.2 Almac Group Business Overview
    • 10.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
    • 10.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 10.16.5 Almac Group Recent Development
  • 13.17 Janssen Global Services
    • 10.17.1 Janssen Global Services Company Details
    • 10.17.2 Janssen Global Services Business Overview
    • 10.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
    • 10.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 10.17.5 Janssen Global Services Recent Development
  • 13.18 Sysmex Corporation
    • 10.18.1 Sysmex Corporation Company Details
    • 10.18.2 Sysmex Corporation Business Overview
    • 10.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
    • 10.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
    • 10.18.5 Sysmex Corporation Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Next Generation Cancer Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Next Generation Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Cepheid
    Koninklijke Philips N.V
    F. Hoffmann-La Roche Ltd
    Qiagen
    Novartis AG
    Abbott
    Thermo Fisher Scientific
    Opko Health
    Myriad Genetics
    Agilent Technologies
    GE Healthcare
    PerkinElmer
    Genomic Health
    Illumina
    Hologic
    Almac Group
    Janssen Global Services
    Sysmex Corporation

    Market segment by Type, the product can be split into
    Next Generation Sequencing
    qPCR & Multiplexing
    DNA Microarrays
    Other
    Market segment by Application, split into
    Hospitals
    Clinics
    Other

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now